Paper Details
- Home
- Paper Details
A sorafenib-sparing effect in the treatment of thyroid carcinoma cells attained by co-treatment with a novel isoflavone derivative and 1,25 dihydroxyvitamin D3.
Author: AizicAsaf, FlissDan M, IzkhakovElena, KnollEsther, KohenFortune, SharonOrli, SomjenDalia, SternNaftali
Original Abstract of the Article :
Sorafenib improves progression-free survival in patients with progressive radioactive iodine-refractory differentiated thyroid carcinoma, but causes severe side effects. Estrogens may accelerate thyroid carcinoma cell growth. Our group recently reported that isoflavone derivative 7-(O)-carboxymethyl...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1016/j.jsbmb.2018.04.013
データ提供：米国国立医学図書館（NLM）
Sorafenib-Sparing Effect in Thyroid Carcinoma: Finding a New Oasis in the Desert of Treatment
Thyroid carcinoma, a type of cancer that affects the thyroid gland, can be a challenging condition to treat. Sorafenib, a tyrosine kinase inhibitor, is often used for the treatment of progressive radioactive iodine-refractory differentiated thyroid carcinoma, but it can cause severe side effects. This study explores the potential of combining sorafenib with a novel isoflavone derivative and 1,25 dihydroxyvitamin D3 to reduce sorafenib dosage and minimize side effects.
A New Approach to Thyroid Carcinoma Treatment: Navigating the Desert of Side Effects
The study investigated the effects of combining a novel isoflavone derivative, 7-(O)-carboxymethyl daidzein conjugated to N-t-boc-hexylenediamine (cD-tboc), and 1,25 dihydroxyvitamin D3 (1.25D) with sorafenib on thyroid carcinoma cells. The results suggest that this combination approach may allow for lower doses of sorafenib, potentially reducing the risk of side effects while maintaining therapeutic efficacy.
Finding Balance in the Desert of Thyroid Cancer Treatment
The study highlights the potential of combination therapies to optimize treatment outcomes for thyroid carcinoma. By exploring synergistic effects between different drugs, we can potentially achieve better therapeutic results while minimizing the risk of side effects. This research provides a promising avenue for developing safer and more effective treatment strategies for thyroid carcinoma.
Dr.Camel's Conclusion
The desert of thyroid carcinoma treatment can be fraught with challenges, but with the development of innovative combination therapies, we can create new oases of hope for those affected by this disease. This study demonstrates the potential of combining sorafenib with other agents to reduce dosage and minimize side effects, paving the way for a more personalized and effective treatment landscape.
Date :
- Date Completed 2019-08-20
- Date Revised 2021-08-16
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.